市場調査レポート

商品コード

1687512

細胞療法市場規模、シェア、成長分析：技術別、タイプ別、細胞タイプ別、細胞源別、用途別、エンドユーザー別、地域別 - 産業予測 2025～2032年

Cell Therapy Market Size, Share, and Growth Analysis, By Technology, By Type, By Cell Type, By Cell Source, By Application, By End-User, By Region - Industry Forecast 2025-2032

出版日: 2025年03月14日
発行: SkyQuest
ページ情報: 英文 157 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 760,921円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 890,134円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,019,347円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=143.57円

全表示
概要
目次

概要

サンプル依頼リストに入れる

細胞療法市場規模は2023年に69億米ドルと評価され、2024年の83億8,000万米ドルから2032年には398億1,000万米ドルに成長し、予測期間（2025年～2032年）のCAGRは21.5％で成長する見通しです。

世界の細胞療法市場は、革新的な治療アプローチが必要とされる変性疾患や慢性疾患の有病率の増加を主な要因として、大きな成長を遂げています。幹細胞研究と再生医療における進歩は、治療展望を拡大し、疾病管理に新たな道を提供しています。細胞研究への多額の投資は、新規治療法の開発をさらに推進し、業界利害関係者に有利な機会を生み出しています。個々の患者のプロファイルに合わせて治療を行う個別化医療に対する需要の高まりも、細胞ベースの治療に対する関心の高まりに寄与しています。しかし、いくつかの課題が市場の成長を阻害する可能性があります。特に小規模の製薬会社や研究機関にとっては、細胞治療の開発・製造にかかる高いコストが法外な負担となる可能性があります。さらに、免疫拒絶反応のリスクが依然として懸念され、患者の安全性を確保するために厳格な試験と検証が必要となります。複雑で厳しい規制当局の承認プロセスは、新しい治療法の商業化をさらに遅らせ、市場参入のハードルとなっています。このような課題にもかかわらず、継続的な調査、技術の進歩、慢性疾患や変性疾患に対する効果的な治療に対する差し迫ったニーズが原動力となって、細胞療法市場は今後数年間で大きく拡大すると予測されています。

北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他欧州地域
アジア太平洋地域
- 中国
- インド
- 日本
- 韓国
- その他アジア太平洋地域
ラテンアメリカ
- ブラジル
- その他ラテンアメリカ地域
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ

競合情報

上位5社の比較
主要企業の市場ポジショニング（2024年）
主な市場企業が採用した戦略
最近の市場動向
企業の市場シェア分析（2024年）
主要企業の企業プロファイル
- 企業の詳細
- 製品ポートフォリオ分析
- 企業のセグメント別シェア分析
- 収益の前年比比較（2022-2024）

主要企業プロファイル

Novartis AG（Switzerland）
Gilead Sciences, Inc.（USA）
Bristol Myers Squibb（USA）
Johnson & Johnson（USA）
Takeda Pharmaceutical Company Limited（Japan）
Bluebird Bio, Inc.（USA）
Mesoblast Limited（Australia）
CRISPR Therapeutics（Switzerland）
Adaptimmune Therapeutics plc（UK）
Fate Therapeutics, Inc.（USA）
Orchard Therapeutics plc（UK）
Gamida Cell Ltd.（Israel）
Allogene Therapeutics, Inc.（USA）
Capricor Therapeutics, Inc.（USA）
Vericel Corporation（USA）
Mustang Bio, Inc.（USA）
Atara Biotherapeutics, Inc.（USA）

結論と提言

Product Code: SQMIG35H2061

Cell Therapy Market size was valued at USD 6.9 Billion in 2023 and is poised to grow from USD 8.38 Billion in 2024 to USD 39.81 Billion by 2032, growing at a CAGR of 21.5% during the forecast period (2025-2032).

The global cell therapy market is experiencing significant growth, primarily driven by the increasing prevalence of degenerative disorders and chronic diseases, which necessitate innovative treatment approaches. Advancements in stem cell research and regenerative medicine are expanding the therapeutic landscape, offering new avenues for disease management. Substantial investments in cell research are further propelling the development of novel therapies, creating lucrative opportunities for industry stakeholders. The rising demand for personalized medicine, which tailors treatments to individual patient profiles, is also contributing to the heightened interest in cell-based therapies. However, several challenges may impede market growth. The high costs associated with the development and manufacturing of cell therapies can be prohibitive, particularly for smaller pharmaceutical companies and research institutions. Additionally, the risk of immune rejection remains a concern, necessitating rigorous testing and validation to ensure patient safety. Complex and stringent regulatory approval processes can further delay the commercialization of new therapies, posing hurdles for market entrants. Despite these challenges, the cell therapy market is projected to expand significantly in the coming years, driven by continuous research, technological advancements, and the pressing need for effective treatments for chronic and degenerative diseases.

Top-down and bottom-up approaches were used to estimate and validate the size of the Cell Therapy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Cell Therapy Market Segments Analysis

Global Cell Therapy Market is segmented by Technology, Type, Cell Type, Cell Source, Application, End-User and region. Based on Technology, the market is segmented into Somatic Cell Technology, Cell Immortalization Technology, Viral Vector Technology, Genome Editing Technology, Cell Plasticity Technology and Three-Dimensional Technology. Based on Type, the market is segmented into Autologous and Allogeneic. Based on Cell Type, the market is segmented into Stem Cell and Non-Stem Cell. Based on Cell Source, the market is segmented into iPSCs, Bone Marrow, Umbilical Cord Blood-Derived Cells, Adipose Tissues and Neural Stem Cell. Based on Application, the market is segmented into Musculoskeletal, Cardiovascular, Gastrointestinal, Neurological, Oncology, Dermatology, Wounds and Injuries, Ocular and Others. Based on End-User, the market is segmented into Hospitals and Clinics, Regenerative Medicine Centres, Diagnostic and Research Centres and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Cell Therapy Market

The global surge in personalized medicine is significantly enhancing the adoption of innovative cell therapies, which are pivotal in addressing individual patient characteristics. By tailoring treatments to each person's unique genetic and molecular profile, these therapies improve efficacy and minimize adverse reactions. For instance, CAR T-cell therapy customizes a patient's immune cells to target specific cancer cells, leading to higher remission rates. This precision reduces the likelihood of treatment rejection and enhances overall patient outcomes. As personalized medicine continues to evolve, the integration of advanced cell therapies is expected to play a crucial role in developing more effective and safer treatments.

Restraints in the Cell Therapy Market

The risk of immune rejection significantly hampers the growth potential of the cell therapy market, particularly affecting the adoption of allogeneic treatments. In these therapies, donor cells are introduced into patients, but the recipient's immune system may recognize these cells as foreign, leading to their elimination. This immune response not only diminishes the therapeutic efficacy but also poses challenges in developing universally compatible cell therapies. Consequently, addressing immune rejection is crucial for advancing the widespread application of allogeneic cell therapies.

Market Trends of the Cell Therapy Market

The global incidence of cancer has risen substantially, intensifying the demand for innovative treatments. Chimeric Antigen Receptor T-cell (CAR-T) therapy, an emerging form of immunotherapy, has shown promise in targeting specific cancer cells by reprogramming a patient's own T-cells. This personalized approach enhances treatment efficacy and reduces the likelihood of adverse effects. The CAR-T cell therapy market is projected to grow significantly, with estimates suggesting a rise from USD 7.31 billion in 2024 to USD 188.84 billion by 2034, reflecting a compound annual growth rate (CAGR) of 36.8% during 2025-2034. Pharmaceutical companies are increasingly investing in CAR-T therapies to expand their portfolios and meet the growing demand for effective cancer treatments. For instance, AstraZeneca's recent acquisition of EsoBiotec, a biotech firm specializing in in-vivo CAR-T cell therapies, underscores the industry's commitment to advancing cell therapy innovations. By aligning with this trend, companies can enhance their market presence and contribute to the development of novel cancer therapies.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Cell Therapy Market Size by Technology & CAGR (2025-2032)

Market Overview
Somatic Cell Technology
Cell Immortalization Technology
Viral Vector Technology
Genome Editing Technology
Cell Plasticity Technology
Three-Dimensional Technology

Global Cell Therapy Market Size by Type & CAGR (2025-2032)

Market Overview
Autologous
Allogeneic

Global Cell Therapy Market Size by Cell Type & CAGR (2025-2032)

Market Overview
Stem Cell
Non-Stem Cell

Global Cell Therapy Market Size by Cell Source & CAGR (2025-2032)

Market Overview
iPSCs
Bone Marrow
Umbilical Cord Blood-Derived Cells
Adipose Tissues
Neural Stem Cell

Global Cell Therapy Market Size by Application & CAGR (2025-2032)

Market Overview
Musculoskeletal
Cardiovascular
Gastrointestinal
Neurological
Oncology
Dermatology
Wounds and Injuries
Ocular
Others

Global Cell Therapy Market Size by End-User & CAGR (2025-2032)

Market Overview
Hospitals and Clinics
Regenerative Medicine Centres
Diagnostic and Research Centres
Others

Global Cell Therapy Market Size & CAGR (2025-2032)

North America (Technology, Type, Cell Type, Cell Source, Application, End-User)
- US
- Canada
Europe (Technology, Type, Cell Type, Cell Source, Application, End-User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Technology, Type, Cell Type, Cell Source, Application, End-User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Technology, Type, Cell Type, Cell Source, Application, End-User)
- Brazil
- Rest of Latin America
Middle East & Africa (Technology, Type, Cell Type, Cell Source, Application, End-User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bluebird Bio, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mesoblast Limited (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CRISPR Therapeutics (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Adaptimmune Therapeutics plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fate Therapeutics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Orchard Therapeutics plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gamida Cell Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Allogene Therapeutics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Capricor Therapeutics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vericel Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mustang Bio, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Atara Biotherapeutics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

細胞療法市場規模、シェア、成長分析：技術別、タイプ別、細胞タイプ別、細胞源別、用途別、エンドユーザー別、地域別 - 産業予測 2025～2032年

Cell Therapy Market Size, Share, and Growth Analysis, By Technology, By Type, By Cell Type, By Cell Source, By Application, By End-User, By Region - Industry Forecast 2025-2032

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と見通し

主な市場の考察

細胞療法市場規模：技術別& CAGR（2025-2032）

細胞療法市場規模：タイプ別& CAGR（2025-2032）

細胞療法市場規模：細胞タイプ別& CAGR（2025-2032）

細胞療法市場規模：細胞源別 & CAGR（2025-2032）

細胞療法市場規模：用途別& CAGR（2025-2032）

細胞療法市場規模：エンドユーザー別& CAGR（2025-2032）

細胞療法市場規模：地域別& CAGR（2025-2032）